The US Food and Drug Administration (FDA) recently approved a medical device that could bring new hope to patients suffering from rheumatoid arthritis (RA), a chronic autoimmune condition often ...

SetPoint Medical today announced the first patients in Chicago have been treated with the SetPoint System, an FDA-approved neuroimmune modulation therapy for adults living with moderately-to-severely ...

Publication of 12-month outcomes reinforces SetPoint Medical’s pioneering role in advancing neuroimmune modulation as a new treatment paradigm for rheumatoid arthritis (RA) VALENCIA, Calif., January ...

Credit: SetPoint Medical. The SetPoint System is a rechargeable neurostimulation device that is implanted on the vagus nerve. Treatment with the SetPoint System, a neuroimmune modulation device, was ...

SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis Four presentations highlight 12-month ...

An innovative new device calms inflammation by delivering a low-voltage jolt of electricity to the vagus nerve. The FDA has approved the SetPoint System, a device implanted in the neck for relieving ...

SetPoint Medical has raised $140 million. This includes $25 million in the second tranche of its Series C financing, as well as $115 million in its Series D financing, co-led by Elevage Medical ...

Procedures performed by Dr. Webster Crowley mark a milestone for neuroimmune modulation therapy in the Midwest SetPoint Medical today announced the first patients in Chicago have been treated with the ...

VALENCIA, Calif., February 03, 2026--(BUSINESS WIRE)--SetPoint Medical today announced the first patients in Chicago have been treated with the SetPoint System, an FDA-approved neuroimmune modulation ...